2-氨基-N-羟基-3-苯丙酰胺 | 36207-44-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-N-羟基-3-苯丙酰胺
• 英文名称: phenylalaninohydroxamic acid
• 英文别名: H-D,L-Phe-NHOH；α-phenylalaninehydroxamic acid；N--hydroxylamin；N-(DL-phenylalanyl) hydroxylamin；(+/-)-2-Amino-3-phenyl-propionohydroxamsaeure；2-Amino-3-phenyl-propionsaeure-hydroxyamid；DL-Phenylalanine hydroxamate；phenylalanine hydroxyamide；Phenylalanin-hydroxyamid；dl-phenylalanine hydroxamic acid；phenylalanine hydroxamate；2-amino-N-hydroxy-3-phenylpropanamide
• CAS: 36207-44-0
• 化学式: C₉H₁₂N₂O₂
• mdl: MFCD19625161
• 分子量: 180.206
• InChiKey: XWQMGESVWMBPAQ-UHFFFAOYSA-N

物化性质

• 密度：
  1.232±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• WGK Germany：
  3
• 海关编码：
  2924299090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : DL-Phenylalanine hydroxamate
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 36207-44-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R36/37/38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C9H12N2O2
Molecular Weight : 180,2 g/mol
CAS-No. : 36207-44-0
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
DL-Phenylalanine hydroxamate
CAS-No. 36207-44-0 Skin Irrit. 2; Eye Irrit. 2; STOT <= 100 %
SE 3; H315, H319, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
DL-Phenylalanine hydroxamate
CAS-No. 36207-44-0 Xi, R36/37/38 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-N-羟基-3-苯丙酰胺 以23%的产率得到1-hydroxy-3-benzyl-5-(2-thienyl)hydropyrazin-2-one
  参考文献：
  名称：

  Inhibitors of anthrax lethal factor activity

  摘要：

  用于预防和治疗炭疽感染的ALF活性特异性抑制剂的方法和组合物。

  公开号：

  US06436933B1
• 作为产物：
  描述：

  DL-苯丙氨酸 在 盐酸 、 羟胺 作用下， 生成 2-氨基-N-羟基-3-苯丙酰胺
  参考文献：
  名称：

  环状异羟肟酸衍生物的合成及其螯合能力和生物活性。

  摘要：

  合成了几种环羟肟酸。它们表现出金属螯合能力和镇痛活性，符合预期。除了这些活性外，其中一些化合物还抑制了微生物的生长。

  DOI：

  10.1248/cpb.36.2323

文献信息

• [EN] NONCRUSHABLE PILL FORMULATIIONS<br/>[FR] FORMULATIONS DE PILULES NON BROYABLES
  申请人：UNIV CALIFORNIA

  公开号：WO2018118903A1

  公开（公告）日：2018-06-28

  Non-crushable pill formulations and methods of using the formulations are disclosed. A non- crushable pill formulation for preventing unintended use of a drug, comprising a polymer, the polymer forming a polymer backbone of the complex; cross-linkers, the cross-linkers connecting the polymer backbone through covalently bonding to form at least one inner cavity within the complex; and the drug, the drug being trapped either covalently or non-covalently in the at least one inner cavity within the complex, wherein the drug is protected from releasing outside of the complex.

  公开了不可压碎的药丸配方和使用这些配方的方法。一种用于防止药物意外使用的不可压碎药丸配方，包括聚合物，该聚合物形成复合体的聚合物骨架；交联剂，通过共价键连接聚合物骨架以形成复合体内的至少一个内腔；以及药物，该药物被共价地或非共价地困在复合体内的至少一个内腔中，使得药物受到保护，不会在复合体外释放。
• Anticancer Activity of Spirocyclic Hydroxamic Acids (Derivatives of 1-Hydroxy-1,4,8-Triazaspiro[4,5]Decan-2-One), Histone Deacetylase Inhibitors
  作者：N. P. Akentieva、A. R. Gizatullin、S. A. Goncharova、T. A. Raevskaya、N. S. Goryachev、N. I. Shkondina、T. R. Prichodchenko、I. V. Vystorop、S. S. Shushanov

  DOI：10.1134/s1990747818040037

  日期：2019.1

  The effect of 10 racemic spirocyclic hydroxamic acids (CHA 1–10, derivatives of 1-hydroxy-1,4,8-triazaspiro[4,5]decan-2-one), containing pharmacophore imidazolidinone and piperidine fragments with different substituents, on the activity of enzyme histone deacetylase (HDAC) was studied. It was shown that CHA (1–10) inhibit HDAC activity in cultured breast cancer cells. It was shown that CHA (1–10) as

  10 种外消旋螺环异羟肟酸（CHA 1-10，1-羟基-1,4,8-三氮杂螺[4,5]癸烷-2-one 的衍生物），含有药效团咪唑啉酮和具有不同取代基的哌啶片段，对研究了酶组蛋白脱乙酰酶（HDAC）的活性。结果表明，CHA (1-10) 抑制培养的乳腺癌细胞中的 HDAC 活性。结果表明，CHA（1-10）作为顺铂和环磷烷多化学疗法的一部分在体内具有显着的化学增敏抗肿瘤活性。在体内肿瘤模型上获得的结果表明，CHA 可以被认为是肿瘤综合化疗的潜在药物成分。
• [EN] DUAL-ENZYME RESPONSIVE PEPTIDES<br/>[FR] PEPTIDES SENSIBLES À DEUX ENZYMES
  申请人：UNIV CALIFORNIA

  公开号：WO2018118902A1

  公开（公告）日：2018-06-28

  An enzyme-responsive peptide and a method off using such enzyme-responsive peptide are disclosed. An enzyme-responsive peptide, the peptide comprising an amino acid having an α-amino group, an α-carboxylic acid group and a ε-amine group, wherein the ε-amine group is covalently bonded with a first group and the α-carboxylic acid is covalently bonded with a second group.

  本发明公开了一种酶响应肽和使用该酶响应肽的方法。酶响应肽包括一个具有α-氨基、α-羧基和ε-胺基的氨基酸，其中ε-胺基与第一基团共价键合，α-羧基与第二基团共价键合。
• New insights into water-soluble and water-coordinated copper 15-metallacrown-5 gadolinium complexes designed for high-field magnetic resonance imaging applications
  作者：Marina A. Katkova、Galina S. Zabrodina、Evgeny V. Baranov、Maria S. Muravyeva、Evgeny A. Kluev、Andrey S. Shavyrin、Grigory Yu Zhigulin、Sergey Yu Ketkov

  DOI：10.1002/aoc.4389

  日期：2018.7

  the Gd(III) ion: Gd(H2O)4[15‐MCCu(II)Glyha‐5](Cl)3 (1(Gd)), Gd(H2O)4[15‐MCCu(II)Alaha‐5](Cl)3 (2(Gd)), Gd(H2O)3[15‐MCCu(II)Phalaha‐5](Cl)3 (3(Gd)) and Gd(H2O)3[15‐MCCu(II)Tyrha‐5](Cl)3 (4(Gd)). In these systems, the Ln(III) central ion is coordinated by five oxygen donor atoms of the ligands and three or four inner‐sphere water molecules. The X‐ray crystal structure of metallacrown Ln(H2O)3,4[15‐MCCu(II)Rha‐5]3+

  需要开发专门设计用于高场磁共振成像（MRI）的造影剂，因为经典Gd（III）造影剂的弛豫效率会随着磁场强度的增加而显着降低。为了探索镧系元素（Ln）15‐MC‐5金属lac的独特结构，我们开发了一系列水溶性Gd（III）水络合物，它们带有氨基异羟肟酸酯（甘氨酸，α‐丙氨酸，α‐苯丙氨酸和α -酪氨酸）配体，其中越来越多的水分子直接与Gd（III）离子配位：Gd（H 2 O）4 [15-MC Cu（II）Glyha -5]（Cl）3（1（Gd）） ，Gd（H 2 O）4 [15-MC Cu（II）Alaha‐5]（Cl）3（2（Gd）），Gd（H 2 O）3 [15-MC Cu（II）Phalaha ‐5]（Cl）3（3（Gd））和Gd（H 2 O）3 [15-MC Cu（II）Tyrha- 5] [Cl）3（4（Gd））。在这些系统中，Ln（III）中心离子由配体的五个氧供体原子和三个或四个内层水分子协调。金属催乳Ln（H
• Arylsulfonamido-substituted hydroxamic acid derivatives
  申请人：Breitenstein Werner

  公开号：US20080275127A1

  公开（公告）日：2008-11-06

  α-Amino hydroxamic acid derivative of the formula I, in which R is C 2 -C 7 -alkyl, which is mono-, di- or trisubstituted by halogen, nitro, lower acyloxy, trifluoromethoxy, cyano, C 3 -C 5 -cycloalkyl or unsubstituted or substituted C 3 -C 6 -heteroaryl comprising one or two heteroatoms selected from the group consisting of O, S and N; or C 3 -C 7 -alkenyl or C 3 -C 7 -alkynyl, which in each case is unsubstituted or mono-, di- or trisubstituted by halogen, nitro, lower acyloxy, trifluoromethoxy, cyano, C 3 -C 5 -cycloalkyl or unsubstituted or substituted C 3 -C 6 -heteroaryl comprising one or two heteroatoms selected from the group consisting of O, S and N; and the other symbols are as defined in claim 1, are described. These compounds are MMP and in particular MMP2 inhibitors and can be used for treatment of MMP dependent diseases, in particular inflammation conditions, rheumatoid arthritis, osteoarthritis, tumors (tumor growth, metastasis, progression or invasion) and pulmonary disorders (e.g. emphysema, COPD).

  本文描述了公式I的α-氨基羟肟酸衍生物，其中R是C2-C7烷基，可以是单取代、双取代或三取代的卤素、硝基、低酰氧基、三氟甲氧基、氰基、C3-C5环烷基或未取代或取代的C3-C6杂环芳基，其中所述杂环芳基包括一个或两个从O、S和N组成的杂原子；或者是C3-C7烯基或C3-C7炔基，每种情况下都未取代或单取代、双取代或三取代的卤素、硝基、低酰氧基、三氟甲氧基、氰基、C3-C5环烷基或未取代或取代的C3-C6杂环芳基，其中所述杂环芳基包括一个或两个从O、S和N组成的杂原子；其他符号如权利要求1中所定义。这些化合物是MMP，特别是MMP2的抑制剂，并可用于治疗MMP依赖性疾病，特别是炎症病症、类风湿性关节炎、骨关节炎、肿瘤（肿瘤生长、转移、进展或侵袭）和肺部疾病（例如肺气肿、COPD）。